Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on March 25, 2008, covering an event that occurred on March 20, 2008. The filing pertains to the authorization of a new Executive Stock Option Bonus Plan for the 2008 fiscal year by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements rather than financial performance metrics.
Material Changes
The primary material change reported is the implementation of the 2008 Executive Stock Option Bonus Plan. Under this plan, executive officers are eligible to receive annual bonuses in the form of common stock options based on the achievement of specified individual and corporate objectives. Additional awards are available for performance exceeding annual individual objectives.
Guidance, Outlook, and Management Commentary
The filing details the maximum stock option awards eligible for named executive officers if all 2008 corporate and individual performance objectives are achieved:
- John M. Maraganore, Ph.D. (Chief Executive Officer): 40,000 options
- Barry E. Greene (President and Chief Operating Officer): 25,000 options
- Patricia L. Allen (Vice President of Finance and Treasurer): 12,500 options
The filing notes that these figures are subject to adjustment in the event of a stock split or similar event affecting the common stock. No specific financial guidance, risk factors, or contingencies regarding the company's operational outlook are provided in this document.
Investor Verification Checklist
- Verify the specific written corporate and individual performance objectives required to trigger the stock option awards.
- Confirm the current status of the 2004 Stock Incentive Plan to ensure sufficient option availability.
- Review subsequent filings to determine if the performance objectives were met and if the options were actually granted.
- Check for any stock splits or capital structure changes that would adjust the maximum award numbers listed.